Lexicon's IBS drug positive in Phase II trial
This article was originally published in Scrip
Executive Summary
A Phase II trial of LX1031 in patients with non-constipating irritable bowel syndrome yielded positive Phase II results, says Lexicon Pharmaceuticals. The company's share price was up 19%, to $1.39, in pre-market trading on Nasdaq on November 13th on the news.